Recent Posts on This Topic | See All >
InNexus Biotechnology awarded federal grantTags: cancer
[Source: Finacial Times] - InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company’s development of DXL™ anti-cancer antibodies.
For more information: InNexus Biotechnology Awarded Federal Grant
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.